Background: Direct Acting Antivirals (DAAs) have revolutionized the treatment of chronic hepatitis-C infection.Genotype-3 is the most common genotype found in India and Kashmir as well and it has the more aggressive nature and leads to increased riskof steatosis and hepatocellular carcinoma. Aims and Objectives: To compare the efficacy and safety in chronic hepatitis C genotype-3 infection in Kashmiri population. Materials and Methods: An observational, Prospective, Open label, Hospital based study carried over a period of two years. Treatment naïve Chronic Hepatitis-C genotype-3 patients were included in the study. Patients were divided in two groups. Group-A: Non-cirrhotics who received Sofosbuvir (400 mg daily) with Daclatasvir. Group BCirrhoticswho received Sofosbuvir (400mg daily) with Daclatasvir (60mg daily) and weight based Ribavarin. Results:260 patients were enrolled. Both males(n=133) and females(n=127) were almost equal in distribution. We observed 97 % (203/210) SVR12 in non-cirrhoticswho received Daclatasvir plus Sofosbuvir treatment regimen. Cirrhotics who received Sofosbuvir plus Daclatasvir along with Ribavirin observed SVR of 86 % (43/50). All patients tolerated the drug regimens well without any serious adverse effect. Conclusion: Once daily oralSofosbuvir plus daclatasvir based therapy is highly efficient and safe in both cirrhotics and non-cirrhotic hepatitis C patients.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
